Clorox Prepares to Show Whether Cost Cuts Can Offset Lingering Volume Pressure

Clorox (NYSE:CLX) reports fiscal third-quarter 2026 earnings on April 30, 2026, before market open, with analysts expecting $1.48 per share on revenue of approximately $1.67 billion. The central question is whether the household products giant can demonstrate that its heavy back-half innovation pipeline and newly completed ERP system are beginning to drive the sequential improvement management has promised, or if persistent category weakness and promotional intensity will continue to pressure results. With the stock down sharply and trading well below all major moving averages, this report will test investor patience with the company's turnaround narrative.

Part 1: Earnings Preview

Clorox manufactures and markets consumer products across cleaning, disinfecting, laundry, food, water filtration, and professional categories, with iconic brands including Clorox bleach, Pine-Sol, Glad, Hidden Valley, Brita, and Kingsford. The company operates through four reportable segments: Health and Wellness, Household, Lifestyle, and International.

For the fiscal third quarter ending March 2026, analysts expect $1.48 per share, up from the $1.45 reported in the same quarter last year (Q3 FY2025). The most recent quarter (Q2 FY2026, ending December 2025) delivered $1.39 per share, missing the $1.43 consensus by 2.80%. The year-over-year comparison shows modest growth of +2.07%, but this comes against a backdrop of significant estimate reductions—the consensus has fallen from $1.57 just weeks ago.

Three key themes define this earnings story:

ERP Implementation Completion and Normalization: Clorox completed the final phase of its enterprise resource planning system in January 2026, ending a multi-year digital transformation. The Q2 results included roughly 1 point of shipment favorability from ERP prebuild that management expects to reverse in Q3, creating a near-term headwind. However, the company projects this normalization will contribute approximately 3.5 points of sales growth and roughly $0.90 in EPS benefits in fiscal 2027 as operations stabilize and automation benefits materialize.

Back-Half Innovation Pipeline and Launch Investment: Management has doubled typical launch-size marketing investment for a heavy slate of new products hitting shelves in late Q3 and early Q4, including a new allergen-destroying cleaner, Glad Leakguard, a litter relaunch, Hidden Valley avocado ranch, and Glad four-flex expansion. The success of these launches is critical to reversing share losses and driving the sequential improvement management has promised, with most shelf resets expected in the current quarter.

Category Weakness and Promotional Environment: Household product categories have been essentially flat (Q2 was roughly -0.1% excluding beauty), with persistent pricing pressure and elevated promotional activity. Management expects category growth of 0–1% in the back half, but recent consumption data has been mixed, and the company faces a challenging comparison as it laps easier year-ago periods. The ability to gain share in this environment while maintaining margin discipline will be closely watched.

Analysts remain cautious heading into the release. The consensus has deteriorated significantly, with estimates for the current quarter down from $1.57 to $1.48 over the past 30 days, and next quarter's estimate falling from $2.09 to $2.17 (though still down 24.39% year-over-year from the $2.87 reported in Q4 FY2025). The full-year fiscal 2026 estimate has dropped from $7.72 to $5.87, reflecting the cumulative impact of category weakness, ERP-related disruptions, and margin pressure. While management reaffirmed guidance on the Q2 call and pointed to early January momentum and share gains, the Street appears skeptical that the back-half recovery will materialize as strongly as hoped.

Part 2: Historical Earnings Performance

Clorox has delivered a mixed earnings track record over the past four quarters, with two beats and two misses against analyst estimates. The most recent quarter (Q2 FY2026, December 2025) saw the company report $1.39 versus the $1.43 consensus, a -2.80% miss. This followed a strong Q1 FY2026 (September 2025) beat of +8.97% ($0.85 actual vs. $0.78 estimate) and an even more impressive Q4 FY2025 (June 2025) beat of +28.12% ($2.87 actual vs. $2.24 estimate).

The pattern reveals significant volatility in execution. The Q4 FY2025 blowout beat of $0.63 above estimates was followed by the Q3 FY2025 (March 2025) miss of -7.64% ($1.45 actual vs. $1.57 estimate), suggesting operational inconsistency during the ERP implementation period. The magnitude of beats and misses has been substantial—ranging from a $0.63 upside surprise to a $0.12 downside miss—indicating that visibility and forecasting accuracy have been challenged.

Looking at the year-over-year progression, Q3 FY2025's $1.45 result provides the baseline for tomorrow's expected $1.48, implying only modest growth. The upcoming quarter faces the ERP shipment reversal headwind that management flagged, which could pressure results despite the innovation pipeline beginning to hit shelves. Investors should watch whether Clorox can return to the beat pattern seen in Q4 and Q1, or if the Q2 miss signals renewed execution challenges as the company navigates the final stages of its transformation.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Clorox typically reports before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 1.09% expanding to 3.69% by Day +1. The Day 0 trading range averages 2.20%, while Day +1 sees an expanded range of 4.67%, indicating that initial reactions often intensify in the following session.

The direction of moves has been highly variable. The most dramatic reaction came after the February 2025 report, when the stock initially rose 0.69% on Day 0 but then plunged -7.24% by Day +1, the largest negative move in the dataset. Conversely, the August 2024 report triggered a strong positive reaction, with the stock up 1.68% on Day 0 and surging +7.42% by Day +1. More recently, the February 2026 report saw a modest Day 0 gain of 1.49% followed by a +2.43% Day +1 move, while November 2025 showed initial weakness (-2.95% Day 0) that partially recovered (+1.17% Day +1).

The pattern suggests investors should prepare for meaningful volatility, with Day +1 moves frequently exceeding 4% in either direction. The stock's tendency to see expanded moves on Day +1 indicates that initial market reactions often prove incomplete, with further reassessment occurring as analysts digest the details and update models.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.01% ($5.70) for the May 15, 2026 monthly expiration, which is notably higher than the historical average Day +1 move of 3.69%. This elevated implied volatility of 43.35% suggests options traders are anticipating above-average post-earnings volatility, potentially reflecting uncertainty around the ERP normalization impact, innovation pipeline traction, and whether management can deliver on its promised sequential improvement.

Part 3: What Analysts Are Saying

Analyst sentiment on Clorox is decidedly bearish, with the consensus rating at 2.67 (between Sell and Hold) and an average price target of $111.40—representing 17.5% upside from the current price of $94.77. However, this modest implied upside masks significant skepticism, as the rating distribution shows 13 Hold ratings, 4 Strong Sells, and just 1 Strong Buy, with zero Moderate Buy or Moderate Sell ratings. The concentration of neutral and negative views reflects widespread concern about the company's near-term prospects.

Sentiment has deteriorated over the past month, with the average recommendation weakening from 2.78 to 2.67 as one analyst downgraded from Hold to Strong Sell. The price target range is wide, spanning from a low of $94.00 (essentially at current levels) to a high of $139.00, indicating sharp disagreement about the company's valuation and recovery potential. The fact that the low-end target sits at the current price suggests at least one analyst sees limited downside protection.

The bearish tilt reflects analyst concerns about category growth remaining flat, persistent promotional intensity pressuring margins, and uncertainty about whether the back-half innovation slate can drive meaningful share gains and revenue acceleration. While management's reaffirmed guidance and completion of the ERP system provide some support, the Street appears to be taking a wait-and-see approach, demanding proof of execution before turning more constructive. The deteriorating sentiment trend heading into earnings suggests analysts are positioning defensively, expecting the company to face continued headwinds in the near term.

Part 4: Technical Picture

Clorox enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing an 88% Sell signal—a significant weakening from 72% Sell last week and 56% Sell last month. This accelerating negative momentum reflects growing technical pressure as the stock has broken down through multiple support levels.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downward momentum heading into the earnings release
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term weakness, though less extreme than the short-term picture
• Long-term (100% Sell): Maximum bearish reading reflects a deeply damaged longer-term trend structure

Strong Strongest trend characteristics indicate the technical deterioration is both severe in magnitude and accelerating in pace, creating a challenging setup for the earnings release.

The stock is trading at $94.77, positioned below all major moving averages: the 5-day ($96.87), 10-day ($99.00), 20-day ($101.63), 50-day ($109.16), 100-day ($108.64), and 200-day ($113.54). This complete breakdown below the moving average structure is particularly concerning, with the stock now trading nearly $19 below its 200-day moving average—a level that typically represents long-term trend support.

The technical setup is decidedly cautionary heading into earnings. With the stock below all moving averages and showing maximum bearish signals across short-term and long-term timeframes, there is little technical support to cushion a disappointing report. The 200-day moving average at $113.54 now represents significant overhead resistance, while the recent low near $94 appears to be the next key support level. The accelerating pace of technical deterioration (88% Sell vs. 56% just a month ago) suggests momentum remains firmly negative, meaning the stock would likely need a significant positive surprise to reverse the technical damage. Conversely, any disappointment could trigger further downside as weak holders exit and technical selling accelerates.